Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH?

The iShares U.S. Pharmaceuticals ETF (IHE) has outperformed VanEck Pharmaceutical ETF (PPH) over the past year, driven by concentrated exposure to Eli Lilly's GLP-1 drugs, delivering 38.2% returns versus PPH's 26.4%. However, PPH offers global diversification with European pharma giants, a higher dividend yield of 1.9%, and nearly identical expense ratios. IHE suits investors seeking recent momentum, while PPH appeals to those prioritizing international exposure and income.